Hematologic Cancers

Conditioning Regimens Produce Similar Long-Term Outcomes in Newly Diagnosed Multiple Myeloma

By

Vicki Moore, PhD

Publish Date September 30, 2022

Conditioning with MEL200 or BUMEL produced similar outcomes at 7 years.

Real-World Data Suggest Tisagenlecleucel Is Effective in Infant B-ALL

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date September 28, 2022

Researchers sought to determine whether tisagenlecleucel was effective would be effective in infant patients with B-ALL

Coagulation Parameters With Cytokine-Release Syndrome and CAR-T Therapy in B-Cell Lymphomas

By

Vicki Moore, PhD

Publish Date September 23, 2022

Researchers sought to determine patterns in coagulation parameters linked to cytokine-release syndrome in patients receiving CAR-T therapy.

First-Line Brentuximab Vedotin With AVD Improves Survival in Stage III or IV Hodgkin Lymphoma

By

Jonathan Goodman, MPhil

Publish Date September 22, 2022

Researchers sought to determine whether adding brentuximab vedotin to AVD would improve survival in patients with stage III or IV Hodgkin lymphoma.

Photon-Counting Detector CT Helps ID Multiple Myeloma Lesions

Publish Date September 22, 2022

Use of PCD CT images with convolutional neural network denoising improves viewing of pathologic abnormalities, detects lytic lesions.